相似文献
1
Review of immune-related adverse events in prostate cancer patients treated with ipilimumab: MD Anderson experience.
Oncogene. 2015 Oct;34(43):5411-7. doi: 10.1038/onc.2015.5. Epub 2015 Feb 9.
2
Ipilimumab in the treatment of prostate cancer.
Future Oncol. 2015;11(1):27-37. doi: 10.2217/fon.14.196.
3
Ipilimumab-induced toxicities and the gastroenterologist.
J Gastroenterol Hepatol. 2015 Apr;30(4):657-66. doi: 10.1111/jgh.12888.
4
A pilot trial of CTLA-4 blockade with human anti-CTLA-4 in patients with hormone-refractory prostate cancer.
Clin Cancer Res. 2007 Mar 15;13(6):1810-5. doi: 10.1158/1078-0432.CCR-06-2318.
5
Combined immunotherapy with granulocyte-macrophage colony-stimulating factor-transduced allogeneic prostate cancer cells and ipilimumab in patients with metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial.
Lancet Oncol. 2012 May;13(5):509-17. doi: 10.1016/S1470-2045(12)70007-4. Epub 2012 Feb 10.
6
Radiographic Profiling of Immune-Related Adverse Events in Advanced Melanoma Patients Treated with Ipilimumab.
Cancer Immunol Res. 2015 Oct;3(10):1185-92. doi: 10.1158/2326-6066.CIR-15-0102. Epub 2015 Jun 22.
7
Review: anti-CTLA-4 antibody ipilimumab: case studies of clinical response and immune-related adverse events.
Oncologist. 2007 Jul;12(7):864-72. doi: 10.1634/theoncologist.12-7-864.
8
Immune-Related Adverse Events, Need for Systemic Immunosuppression, and Effects on Survival and Time to Treatment Failure in Patients With Melanoma Treated With Ipilimumab at Memorial Sloan Kettering Cancer Center.
J Clin Oncol. 2015 Oct 1;33(28):3193-8. doi: 10.1200/JCO.2015.60.8448. Epub 2015 Aug 17.
9
Management of immune-related adverse events and kinetics of response with ipilimumab.
J Clin Oncol. 2012 Jul 20;30(21):2691-7. doi: 10.1200/JCO.2012.41.6750. Epub 2012 May 21.
10
Development of ipilimumab: contribution to a new paradigm for cancer immunotherapy.
Semin Oncol. 2010 Oct;37(5):533-46. doi: 10.1053/j.seminoncol.2010.09.015.
引用本文的文献
1
Immunotherapy-Related Hypophysitis: A Narrative Review.
Cancers (Basel). 2025 Jan 27;17(3):436. doi: 10.3390/cancers17030436.
2
Identification of CBPA as a New Inhibitor of PD-1/PD-L1 Interaction.
Int J Mol Sci. 2023 Feb 16;24(4):3971. doi: 10.3390/ijms24043971.
3
Short Review on Advances in Hydrogel-Based Drug Delivery Strategies for Cancer Immunotherapy.
Tissue Eng Regen Med. 2022 Apr;19(2):263-280. doi: 10.1007/s13770-021-00369-6. Epub 2021 Oct 1.
4
Progress in Neoantigen Targeted Cancer Immunotherapies.
Front Cell Dev Biol. 2020 Jul 30;8:728. doi: 10.3389/fcell.2020.00728. eCollection 2020.
5
Autoimmune antibodies correlate with immune checkpoint therapy-induced toxicities.
Proc Natl Acad Sci U S A. 2019 Oct 29;116(44):22246-22251. doi: 10.1073/pnas.1908079116. Epub 2019 Oct 14.
6
Pneumonitis and concomitant bacterial pneumonia in patients receiving pembrolizumab treatment: Three case reports and literature review.
Medicine (Baltimore). 2019 Jun;98(25):e16158. doi: 10.1097/MD.0000000000016158.
7
Autoimmune Endocrine Dysfunctions Associated with Cancer Immunotherapies.
Int J Mol Sci. 2019 May 24;20(10):2560. doi: 10.3390/ijms20102560.
8
Systematic review and case series: flexible sigmoidoscopy identifies most cases of checkpoint inhibitor-induced colitis.
Aliment Pharmacol Ther. 2019 Jun;49(12):1474-1483. doi: 10.1111/apt.15263. Epub 2019 Apr 29.
9
Uveitis in Patients Treated with CTLA-4 and PD-1 Checkpoint Blockade Inhibition.
Ocul Immunol Inflamm. 2020;28(2):217-227. doi: 10.1080/09273948.2019.1577978. Epub 2019 Mar 1.
10
[Immunotherapy for the treatment of prostate cancer-a comeback?].
Urologe A. 2018 Nov;57(11):1342-1345. doi: 10.1007/s00120-018-0790-4.
本文引用的文献
1
Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial.
Lancet Oncol. 2014 Jun;15(7):700-12. doi: 10.1016/S1470-2045(14)70189-5. Epub 2014 May 13.
2
Immune-mediated adverse events associated with ipilimumab ctla-4 blockade therapy: the underlying mechanisms and clinical management.
Scientifica (Cairo). 2013;2013:857519. doi: 10.1155/2013/857519. Epub 2013 Apr 17.
3
Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma.
J Exp Med. 2013 Aug 26;210(9):1695-710. doi: 10.1084/jem.20130579. Epub 2013 Jul 29.
4
Ipilimumab and its toxicities: a multidisciplinary approach.
Oncologist. 2013 Jun;18(6):733-43. doi: 10.1634/theoncologist.2012-0483. Epub 2013 Jun 17.
5
Development of ipilimumab: a novel immunotherapeutic approach for the treatment of advanced melanoma.
Ann N Y Acad Sci. 2013 Jul;1291(1):1-13. doi: 10.1111/nyas.12180. Epub 2013 Jun 17.
6
The price of tumor control: an analysis of rare side effects of anti-CTLA-4 therapy in metastatic melanoma from the ipilimumab network.
PLoS One. 2013;8(1):e53745. doi: 10.1371/journal.pone.0053745. Epub 2013 Jan 14.
7
Anti-IL-17 mAbs herald new options in psoriasis.
Nat Biotechnol. 2012 Jun 7;30(6):475-7. doi: 10.1038/nbt0612-475.
8
Management of immune-related adverse events and kinetics of response with ipilimumab.
J Clin Oncol. 2012 Jul 20;30(21):2691-7. doi: 10.1200/JCO.2012.41.6750. Epub 2012 May 21.
9
Immunologic correlates of the abscopal effect in a patient with melanoma.
N Engl J Med. 2012 Mar 8;366(10):925-31. doi: 10.1056/NEJMoa1112824.
10
Ipilimumab and a poxviral vaccine targeting prostate-specific antigen in metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial.
Lancet Oncol. 2012 May;13(5):501-8. doi: 10.1016/S1470-2045(12)70006-2. Epub 2012 Feb 10.
Zotero 插件